Voyager Therapeutics Inc. (VYGR) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Voyager Therapeutics Inc. (NASDAQ: VYGR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.76 (-4.35% 1D, market cap $108.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VYGR ranks #1014 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VYGR carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LENZ (LENZ Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M) and BDTX (Black Diamond Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M). Among the 5-stock peer group, VYGR leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).
Per VYGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001640266), Voyager Therapeutics Inc. generated $40.4M in revenue (-49.5% YoY), -$119.7M in net income, and -$135.1M in free cash flow against $252.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.5 (OVERSOLD (<32))
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While VYGR currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.71) and Max Pain ($1.85) forces dealer call-delta covering toward $5.75.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Voyager Therapeutics Inc. (VYGR) dropped -4.35% to $1.76, trading at 2% of its 52-week range ($1.68 – $5.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentat
- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr. Sandrock expected to remain
Swartz is expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer (CEO) in Q1 2027, following the receipt of initial acute safety data from a clinical trial of Voyager’s investigational tau
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -49.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VYGR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VYGR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Voyager Therapeutics Inc. (VYGR) ranks #1014 by composite RQD confidence (19/100, grade E) and #648 by equity capitalization ($108.4M). Within this direct 5-issuer industry benchmark cohort, VYGR leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with VYGR at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VYGR
ACTIVE
Voyager Therapeutics Inc. | E | 19/100 | — | — | -35.0% | -4.35% | $108.4M | Benchmark Subject |
| LENZ LENZ Therapeutics Inc. | D | 44/100 | — | 96.0% | -27.8% | +8.72% | $109.7M | /lenz-vs-vygr → |
| BDTX Black Diamond Therapeutics Inc. | C- | 59/100 | — | — | 10.8% | +1.64% | $106.9M | /bdtx-vs-vygr → |
| ENGN enGene Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -3.16% | $102.5M | /engn-vs-vygr → |
| OTLK Outlook Therapeutics Inc. | D- | 38/100 | — | 4.0% | -35.0% | -9.43% | $120.1M | /otlk-vs-vygr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Voyager Therapeutics Inc. (VYGR) reported GAAP revenue of $40.4M (-49.5% vs. FY2024 revenue of $80.0M , and -83.9% cumulative change since FY2023) , GAAP net income of -$119.7M, operating cash flow of -$132.5M, and free cash flow of -$135.1M (-617.2% YoY). On the balance sheet, VYGR closed FY2025 with $252.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.4M | -$119.7M | -$132.5M | -$135.1M | $252.3M | — |
| FY2024 (FY) | 2024-12-31 | $80.0M | -$65.0M | -$15.3M | -$18.8M | $393.1M | — |
| FY2023 (FY) | 2023-12-31 | $250.0M | $132.3M | $77.9M | $77.9M | — | — |
As of 2026-11-01, Voyager Therapeutics Inc. (NASDAQ: VYGR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.76 (-4.35% 1D, market cap $108.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VYGR ranks #1014 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VYGR carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LENZ (LENZ Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M) and BDTX (Black Diamond Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M). Among the 5-stock peer group, VYGR leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).
Per VYGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001640266), Voyager Therapeutics Inc. generated $40.4M in revenue (-49.5% YoY), -$119.7M in net income, and -$135.1M in free cash flow against $252.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VYGR last traded at $1.76 (-4.35% on volume of 659,901 shares), positioning the stock -35.06% below its 50-day simple moving average ($2.71) and -49.13% below its 200-day simple moving average ($3.46). Across its 52-week range of $1.68 to $5.48, VYGR sits at the 2.1% percentile with a 14-day RSI of 29.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.54 to $1.98).
Why VYGR Stock dropped -4.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.